WilmerHale represented Kala Pharmaceuticals, Inc. in its follow-on public offering of 16,979,371 shares of its common stock, reflecting a partial exercise of the underwriters’ option to purchase additional shares, for aggregate gross proceeds to Kala of approximately $134.0 million. The offering priced on March 10, 2020 at $7.89 per share and closed on March 13, 2020. The option shares closed on April 3, 2020.
The WilmerHale deal team representing Kala included Lia Der Marderosian, Scott Lunin, Andrea Sorrentino, Taylor Beech and Alex Bernstein.